Physician

Joseph F Andrews, M.D.

According to 2025 Medicare claims, Joseph Andrews, M.D. (NPI: 1548321714) practices dermatology in the Dover, DE market, with the plurality of this provider's patient population coming from Kent, DE. This provider's primary affiliated billing organization is PANZER DERMATOLOGY ASSOCIATES (NPI: 1740201995; TIN: 510270514) and primary practice location at 19904-3529.

Andrews' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,054 traditional Medicare patients, billed 5,220 HCPCS/CPT codes, and received $246,916 in Medicare payments. The top billing code was 17110 (Destruction of skin growth, 1-14 growths). Part D data shows 1,074 prescription claims across 395 beneficiaries totaling $222,705 in drug costs, led by Otezla (Apremilast). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $419,091 to $246,916. In contrast, Part D prescription costs have moved sharply higher in recent years, from $142,648 to $222,705. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$210K$419K2015 Medicare payment: $419,091 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $345,450 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $360,159 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $371,163 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $336,841 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $270,859 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $333,598 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $295,909 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $264,376 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $246,916 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20151,8508,444$419,091
20161,6897,003$345,450
20171,7587,845$360,159
20181,7228,020$371,163
20191,4236,224$336,841
20201,0814,925$270,859
20211,3295,666$333,598
20221,1925,577$295,909
20231,1144,984$264,376
20241,0545,220$246,916

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$132K$264K2015 Drug cost: $142,648 (USD; Tot_Drug_Cst)2016 Drug cost: $138,925 (USD; Tot_Drug_Cst)2017 Drug cost: $97,325 (USD; Tot_Drug_Cst)2018 Drug cost: $95,040 (USD; Tot_Drug_Cst)2019 Drug cost: $62,293 (USD; Tot_Drug_Cst)2020 Drug cost: $56,449 (USD; Tot_Drug_Cst)2021 Drug cost: $236,744 (USD; Tot_Drug_Cst)2022 Drug cost: $264,487 (USD; Tot_Drug_Cst)2023 Drug cost: $256,150 (USD; Tot_Drug_Cst)2024 Drug cost: $222,705 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20155051,462$142,648
20164561,301$138,925
20174491,299$97,325
20185001,313$95,040
20194151,102$62,293
2020324955$56,449
20214371,462$236,744
20223861,176$264,487
20233671,076$256,150
20243951,074$222,705

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17110Destruction of skin growth, 1-14 growths378470$74
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more8371,113$60
99212Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more181202$40
17000Destruction of precancer skin growth, 1 growth391484$36
17003Destruction of precancer skin growth, 2-14 growths2921,638$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
OtezlaApremilast11340$56,089
Triamcinolone AcetonideTriamcinolone Acetonide2266,210$3,020
FluorouracilFluorouracil461,413$2,924
Clobetasol PropionateClobetasol Propionate431,058$2,080
MetronidazoleMetronidazole28799$1,379

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Joseph F. Andrews, M.D.?

Tedicare shows public-source Medicare data for Joseph F. Andrews, M.D. (NPI 1548321714), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Joseph F. Andrews, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Joseph F. Andrews, M.D.?

Joseph F. Andrews, M.D. is linked to PANZER DERMATOLOGY ASSOCIATES (billing NPI 1740201995) in the available physician profile data.

Does Joseph F. Andrews, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.